This site is currently not optimized for mobile devices. For the best user experience, please access the site via a device with a wider screen such as a desktop or laptop.

For full functionality of this site it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser.

Once enabled, click here to view the site.

signup link button why should I sign up?
Login as Volunteer Login as Study team member
OR

Studies you may be eligible for. 13

Based on the information you provided, we found the following studies.

  • A First-In-Human Study of Dosing with REGN2810 as Single Therapy and in Combination with Other Anti-Cancer Therapies in Patients with Advanced Malignancies Study purpose: find safe dose of REGN2810 given alone or in combination therapies;measure levels of REGN2810 in blood; evaluate if REGN2810 given alone or in combination w/other therapies will cause tumor shrinkage;test different dose levels of REGN2810, radiotherapy, GM-CSF, and cyclophosphamide. This study is researching all of the following topics: Bladder cancer Breast cancer Cervical cancer Colorectal / Colon / Rectal cancer Esophagus cancer HCC, Liver cancer Kidney Cancer ( Malignant tumor of kidney ) Laryngeal cancer, Cancer of the larynx, Voice box cancer Lung cancer Oral / Mouth cancer Ovarian cancer Pancreatic cancer Prostate cancer Stomach cancer, Gastric cancer ( Malignant tumor of stomach ) Thyroid cancer This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 18 years old
  • A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects with Advanced Non-small Cell Lung Cancer The main purpose of this study is to find the best doses of MEDI4736 and tremelimumab and to check how safe and tolerable MEDI4736 and tremelimumab are when given together in subjects with advanced non-small cell lung cancer. This study is researching all of the following topics: Lung cancer This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 18 years old
  • Open-Label Phase 2 Study of Entrectinib (RXDX-101-02) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements This study will evaluate the safety (side effects) and antitumor activity of entrectinib in subjects with advanced cancer, based on certain types of DNA defect or damage. This study is researching all of the following topics: Colon Cancer ( Malignant tumor of colon ) Colorectal / Colon / Rectal cancer Lung cancer This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 18 years old
  • Phase II study of ponatinib for advanced cancers with genomic alterations in fibroblastic growth factor receptor (FGFR) and other genomic targets (KIT, PDGFRa, RET FLT3, ABL1) The purpose of this study is to find out what effects; good and/or bad, ponatinib has on you and your cancer. Your body has proteins that are involved in a cancer’s ability to grow and survive. The drug, Ponatinib, may prevent these proteins from causing cancer growth. This study is researching all of the following topics: Bladder cancer Breast cancer Colon Cancer ( Malignant tumor of colon ) Colorectal / Colon / Rectal cancer Esophagus cancer Kidney Cancer ( Malignant tumor of kidney ) Lung cancer Ovarian cancer Pancreatic cancer Prostate cancer Thyroid cancer Uterine / Uterus cancer This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 18 years old
  • A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients with Locally Advanced Non-Small Cell Lung Cancer Use Fluorodeoxyglucose–Positron Emission Tomography (FDG-PET, a PET scan) + Ventilation/Perfusion Single Photon Emission Computerized Tomography (V/Q SPECT, a perfusion scan), before + during treatment to see if this helps predict how well the treatment works + your lung functions during treatment. This study is researching all of the following topics: Lung cancer This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 18 years old
  • Phase II study of MK-3475 as Maintenance Therapy in Extensive Stage Small Cell Lung Cancer (SCLC) Patients The purpose of this research study is to evaluate the ability of MK-3475 to control your cancer for a longer period of time following completion of initial chemotherapy. MK-3475 is an investigational drug for your type of cancer. This study is researching all of the following topics: Lung cancer This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 18 years old
  • A Phase 1, Open-label, Dose Escalation, Safety and Tolerability Study of Investigational Drug INCB054828 in Subjects with Advanced Malignancies Study goals: determine dose that is safe and tolerable in people with advanced cancer and select the doses that will be studied further; see how INCB054828 acts on and in the body; see effect INCB054828 has on the growth of your cancer; see action of INCB054828 in the body over a period of time This study is researching all of the following topics: Bladder cancer Cervical cancer Colon Cancer ( Malignant tumor of colon ) Colorectal / Colon / Rectal cancer Kidney Cancer ( Malignant tumor of kidney ) Lung cancer Multiple myeloma Prostate cancer This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 18 years old
  • Personalized Adaptive Radiation Therapy with Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer with Genomic Driver Mutations The purpose of this study is to determine if the combination of FDG-PET/CT ¿adapted radiation therapy plus targeted therapy with either erlotinib (Tarceva) or crizotinib (Xalkori) is safe and effective in people with your stage and type of lung cancer. This study is researching all of the following topics: Lung cancer This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 18 years old
  • A Pilot Study of investigational drug MPDL3280A (PD-L1 Antibody Therapy and Hypofractionated Image-guided Radiotherapy (HIGRT) in Patients with Metastatic Non-Small Cell Lung Cancer Purpose: see if a brief course of radiation therapy given to one area affected by the cancer will improve chances of responding to immuno-therapy MPDL3280A; see if prior treatment with radiation will allow improved recognition of the cancer by the body¿s immune cells in the presence of MPDL3280A. This study is researching all of the following topics: Lung cancer This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 18 years old
  • Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of investigational drug INCB054329 (Study Drug) in Subjects With Advanced Malignancies (INCB 54329-101) Study purpose:determine dose that is safe and tolerable and select the doses that will be studied further;understand how INCB054329 enters and leaves the body over time;understand how INCB054329 acts on and in the body;observe any effects INCB054329 may have on the growth of certain types of cancers This study is researching all of the following topics: ALL ( Acute lymphoblastic leukemia ) Breast cancer CLL ( Chronic lymphocytic leukemia) Colon Cancer ( Malignant tumor of colon ) Lung cancer Pancreatic cancer Prostate cancer This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 18 years old
Showing 1-10 of 13 studies
Show more studies